U.S. pharma big copyright scrapped two experimental weight loss tablets last yr—a the moment-everyday pill, lotiglipron, as a result of elevated liver enzymes and a twice-day-to-day capsule, danuglipron, resulting from robust Uncomfortable side effects—but CEO Albert Bourla has explained the company is determined to “Engage in and acquire”